Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

Jean Louis Vincent; Gordon R. Bernard; Richard Beale; Christopher J. Doig; Christian Putensen; Jean-François Dhainaut; Antonio Artigas; Roberto Fumagalli; William L. Macias; Theressa J. Wright; Kar Wong; David P. Sundin; Mary Ann Turlo; Jonathan Janes

doi:10.1097/01.ccm.0000181729.46010.83

Shared by

Jean Louis Vincent

Université Libre de Bruxelles

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

Article 2005 en

Authors

Jean Louis Vincent
Université Libre de Bruxelles
GB
Gordon R. Bernard
RB
Richard Beale

Abstract

1 min read

ENHANCE provides supportive evidence for the favorable benefit/risk ratio observed in PROWESS and suggests that more effective use of drotrecogin alfa (activated) might be obtained by initiating therapy earlier.

Discussion(0)

No comments yet. Be the first to comment.

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

Abstract

Discussion(0)

Related publications

Drotrecogin alfa (activated) in the treatment of severe sepsis

Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis

Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis

The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

Related publications

Article2006
Drotrecogin alfa (activated) in the treatment of severe sepsis
Article2006

Article2007
Drotrecogin Alfa (Activated) in the Treatment of Severe Sepsis
Article2007

Article2006
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Article2006

Article2004
The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
Article2004

Article2004
The incidence of serious bleeding events in a global, single-arm, open-label trial of Drotrecogin alfa (activated) in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
Article2004